Former AstraZeneca China Oncology Head Yin Min Joins BeiGene as Chief Commercial Officer for Greater China
Dec 10, 2021 11:14
CST Updated
11:14
AstraZeneca
Biopharmaceutical Manufacturer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
On December 9, AstraZeneca announced that Ms. Yin Min, General Manager of its China Oncology Business Unit, will leave the company, with her last working day being December 31.
Today (December 10), BeOne Medicines officially announced that Ms. Yin Min will join BeOne Medicines in January 2022 as the Chief Commercial Officer for Greater China. She will also become a member of the company’s China leadership team and Global Executive Committee.
*Disclaimer: This article was written by an author who has settled in Sina Medicine News. The views expressed in this article are those of the author and do not represent the position of Sina Medicine News.